Alcon and RxSight will develop adjustable presbyopia-correcting intraocular lenses that could allow surgeons to refine vision after cataract surgery, although the programme still faces clinical, regulatory and workflow risks.
Alterity Therapeutics has secured an FDA-aligned Phase 3 pathway for ATH434 in multiple system atrophy, with one pivotal study potentially supporting an approval application.
Egg Medical has launched EggNest Complete 2.0, a construction-free radiation protection system designed to reduce scatter exposure across cath labs and interventional procedure rooms.
Novartis is acquiring Myricx Bio for up to $1.5 billion to gain control of a new NMT inhibitor payload platform, but the lead antibody-drug conjugates have not yet entered human trials.
Beckman Coulter Diagnostics has secured European clearance for its automated Access p-Tau217 blood test, potentially widening access to Alzheimer’s biomarker testing while raising questions about reimbursement, intermediate results and clinical interpretation.
ITM’s lutetium-177 edotreotide extended median progression-free survival to 23.9 months versus 14.1 months with everolimus, strengthening its regulatory and commercial case in advanced neuroendocrine tumours.
Grey Matters Health’s planned NovaScan clinic in Florida will use the CareMiBrain dedicated PET system to expand access to amyloid imaging, while testing whether specialist neuroimaging can become a scalable outpatient service.
Read how Insulet’s Omnipod 5 Spain launch could reshape tubeless insulin delivery, reimbursement and connected diabetes care.
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Discover why Ionis' REVEAL enrollment turns obudanersen into a decisive Phase 3 test for Angelman syndrome treatment.